Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

LEO Pharma

- PMLiVE

LEO Pharma’s Anzupgo cream progresses to phase 3 trial for lichen sclerosus

There are currently no approved treatments specifically indicated for LS in the US or Europe

- PMLiVE

Novo Nordisk announces positive results for CagriSema in type 2 diabetes

CagriSema improved weight loss and blood glucose control compared to semaglutide alone across all tested doses

- PMLiVE

Major prostate cancer screening trial launched in UK

The £42m Transform trial will recruit men aged 50-74, with a lower age limit of 45 for some men

- PMLiVE

LEO Pharma receives NICE approval for chronic hand eczema cream

The cream can now be prescribed for patients when topical corticosteroids have not worked or are not suitable

- PMLiVE

Physician-driven, AI-supported: addressing the clinical trial access gap

To open up more clinical paths for patients, HCPs need simpler search tools, better access to information and integrated referral systems that fit into their clinical workflows

- PMLiVE

Bioxodes appoints Philippe Monteyne as new chairman of the board

The appointment comes as the company releases phase 2a data for its intracerebral haemorrhage treatment

Woman holding weight loss injection

Why patients drop out of weight management trials and what you can do about it

Discover the key barriers to retention in obesity and weight-management trials and explore actionable, patient-centered strategies to improve engagement, outcomes, and data reliability.

Cuttsy + Cuttsy

- PMLiVE

LEO’s Anzupgo granted FDA approval to treat moderate-to-severe chronic hand eczema

The cream is now the first treatment approved by the regulator specifically for this patient population

- PMLiVE

LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront

Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis

- PMLiVE

LEO Pharma and the Parker Institute join forces to advance dermatology research

The alliance will aim to discover molecules that could be incorporated into wider pharmaceutical research

- PMLiVE

LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe

Approximately 125 million people worldwide are affected by some form of the inflammatory condition

- PMLiVE

LEO and DEBRA Research partner to advance epidermolysis bullosa treatments

There is currently no cure for the group of rare inherited skin disorders

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links